[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CR20200089A - Compuestos espirocíclicos y sus métodos de preparación y uso - Google Patents

Compuestos espirocíclicos y sus métodos de preparación y uso

Info

Publication number
CR20200089A
CR20200089A CR20200089A CR20200089A CR20200089A CR 20200089 A CR20200089 A CR 20200089A CR 20200089 A CR20200089 A CR 20200089A CR 20200089 A CR20200089 A CR 20200089A CR 20200089 A CR20200089 A CR 20200089A
Authority
CR
Costa Rica
Prior art keywords
making
methods
same
compounds
spirocycle
Prior art date
Application number
CR20200089A
Other languages
English (en)
Inventor
Olivia D Weber
Michael B Shaghafi
Cheryl A Grice
Todd K Jones
Daniel J Buzard
Original Assignee
Lundbeck La Jolla Research Center Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck La Jolla Research Center Inc filed Critical Lundbeck La Jolla Research Center Inc
Publication of CR20200089A publication Critical patent/CR20200089A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

En la presente se proporcionan compuestos y composiciones útiles como moduladores de MAGL. Además, los compuestos y las composiciones en cuestión son útiles para el tratamiento del dolor.
CR20200089A 2017-08-29 2018-08-28 Compuestos espirocíclicos y sus métodos de preparación y uso CR20200089A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762551721P 2017-08-29 2017-08-29
PCT/US2018/048372 WO2019046318A1 (en) 2017-08-29 2018-08-28 SPIROCYCLIC COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF

Publications (1)

Publication Number Publication Date
CR20200089A true CR20200089A (es) 2020-04-08

Family

ID=65527860

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20200089A CR20200089A (es) 2017-08-29 2018-08-28 Compuestos espirocíclicos y sus métodos de preparación y uso

Country Status (27)

Country Link
US (1) US11142526B2 (es)
EP (1) EP3675847B1 (es)
JP (1) JP7257387B2 (es)
KR (1) KR20200046061A (es)
CN (1) CN111050765B (es)
AU (1) AU2018323459A1 (es)
BR (1) BR112020004101A2 (es)
CA (1) CA3072923A1 (es)
CL (1) CL2020000462A1 (es)
CO (1) CO2020001724A2 (es)
CR (1) CR20200089A (es)
DO (1) DOP2020000039A (es)
EA (1) EA202090312A1 (es)
EC (1) ECSP20013337A (es)
ES (1) ES2952332T3 (es)
GE (1) GEP20217327B (es)
IL (1) IL272580B (es)
JO (1) JOP20200023A1 (es)
MA (1) MA50041A (es)
MX (1) MX2020002251A (es)
NI (1) NI202000014A (es)
PE (1) PE20200664A1 (es)
PH (1) PH12020500372A1 (es)
SG (1) SG11202001022TA (es)
UA (1) UA126685C2 (es)
WO (1) WO2019046318A1 (es)
ZA (1) ZA202001208B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015508407A (ja) 2012-01-06 2015-03-19 アビデ セラピューティクス，インク． カルバメート化合物およびその製造および使用
WO2017197192A1 (en) 2016-05-12 2017-11-16 Abide Therapeutics, Inc. Spirocycle compounds and methods of making and using same
JOP20190107A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
US11161856B2 (en) 2017-08-29 2021-11-02 H. Lundbeck A/S Spirocycle compounds and methods of making and using same
WO2019046318A1 (en) 2017-08-29 2019-03-07 Abide Therapeutics, Inc. SPIROCYCLIC COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF
CN116096723A (zh) * 2020-08-26 2023-05-09 豪夫迈·罗氏有限公司 用作magl抑制剂的杂环化合物
TW202229255A (zh) 2020-11-13 2022-08-01 丹麥商Ｈ 朗德貝克公司 Magl抑制劑

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1368354A1 (en) * 2001-03-07 2003-12-10 Pfizer Products Inc. Modulators of chemokine receptor activity
WO2008023720A1 (fr) 2006-08-23 2008-02-28 Astellas Pharma Inc. COMPOSÉ D'URÉE OU SEL DUDIT COMPOSé
MX2010009727A (es) 2008-03-05 2010-09-28 Targacept Inc Amidas selectivas del subtipo del receptor nicotinico de acetilcolina de diazabicicloalcanos.
FR2941696B1 (fr) 2009-02-05 2011-04-15 Sanofi Aventis Derives d'azaspiranyl-alkylcarbamates d'heterocycles a 5 chainons, leur preparation et leur application en therapeutique
WO2010141817A1 (en) 2009-06-05 2010-12-09 Janssen Pharmaceutica Nv Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase
CN102575076B (zh) 2009-09-29 2014-08-20 普立万公司 具有模拟金属或珠光外观的聚酯制品
DK2491038T3 (da) 2009-10-23 2016-07-18 Janssen Pharmaceutica Nv Disubstituerede octahydropyrrolo [3,4-c]pyrroler som orexin receptormodulatorer
EP2542083B1 (en) 2010-03-04 2015-05-06 Merck Sharp & Dohme Corp. Positive allosteric modulators of mglur2
FR2960875B1 (fr) 2010-06-04 2012-12-28 Sanofi Aventis Derives de carbamates d'hexafluoroisopropyle, leur preparation et leur application en therapeutique
EP2444084A1 (en) 2010-10-21 2012-04-25 Centro Nacional de Investigaciones Oncológicas (CNIO) Use of PI3K inibitors for the treatment of obesity
JP2015508407A (ja) 2012-01-06 2015-03-19 アビデ セラピューティクス，インク． カルバメート化合物およびその製造および使用
BR112015004111A2 (pt) 2012-09-25 2017-07-04 Hoffmann La Roche novos derivados bicíclicos
MX2015017961A (es) 2013-07-03 2016-10-14 Abide Therapeutics Inc Compuestos orgánicos pirrolo-pirrol carbamato y relacionados, composiciones farmacéuticas y usos médicos de los mismos.
WO2015179559A2 (en) * 2014-05-21 2015-11-26 Abide Therapeutics, Inc. Pyrazole compounds and methods of making and using same
MX2017011997A (es) 2015-03-18 2018-05-28 Abide Therapeutics Inc Carbamatos de piperacina y metodos de preparacion y uso.
EP3328849B9 (en) 2015-07-31 2021-01-06 Pfizer Inc. 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors
US10385057B2 (en) 2015-11-20 2019-08-20 Lundbeck La Jolla Research Center, Inc. Pyrazole compounds and methods of making and using same
MX2018011729A (es) 2016-03-31 2019-01-10 Takeda Pharmaceuticals Co Compuesto heterociclico.
WO2017197192A1 (en) 2016-05-12 2017-11-16 Abide Therapeutics, Inc. Spirocycle compounds and methods of making and using same
JOP20190050A1 (ar) 2016-09-23 2019-03-20 Bial Portela & C? S A مثبطات دوبامين-b-هيدروكسيلاز تخترق حاجز المخ الدموي
JOP20190106A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
JOP20190107A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
HUE064559T2 (hu) 2016-11-16 2024-03-28 H Lundbeck As MAGL inhibitor kristályos formája
KR20190085046A (ko) 2016-11-16 2019-07-17 어바이드 테라퓨틱스, 인크. 약학 제제
JOP20190105A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
US11161856B2 (en) 2017-08-29 2021-11-02 H. Lundbeck A/S Spirocycle compounds and methods of making and using same
WO2019046318A1 (en) 2017-08-29 2019-03-07 Abide Therapeutics, Inc. SPIROCYCLIC COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF

Also Published As

Publication number Publication date
CN111050765B (zh) 2024-01-02
ECSP20013337A (es) 2020-04-22
IL272580A (en) 2020-03-31
RU2020107163A (ru) 2021-09-30
SG11202001022TA (en) 2020-03-30
AU2018323459A1 (en) 2020-02-20
MX2020002251A (es) 2020-07-20
NI202000014A (es) 2020-07-28
EP3675847A4 (en) 2021-01-06
EP3675847A1 (en) 2020-07-08
CN111050765A (zh) 2020-04-21
JP2020532545A (ja) 2020-11-12
IL272580B (en) 2022-09-01
EP3675847C0 (en) 2023-07-12
CL2020000462A1 (es) 2020-07-10
EP3675847B1 (en) 2023-07-12
WO2019046318A1 (en) 2019-03-07
CA3072923A1 (en) 2019-03-07
MA50041A (fr) 2020-07-08
UA126685C2 (uk) 2023-01-11
GEP20217327B (en) 2021-12-10
BR112020004101A2 (pt) 2020-09-24
PE20200664A1 (es) 2020-06-11
CO2020001724A2 (es) 2020-02-28
US20200255427A1 (en) 2020-08-13
JOP20200023A1 (ar) 2020-02-02
PH12020500372A1 (en) 2020-12-07
US11142526B2 (en) 2021-10-12
ZA202001208B (en) 2021-08-25
EA202090312A1 (ru) 2020-08-05
DOP2020000039A (es) 2020-08-31
ES2952332T3 (es) 2023-10-30
RU2020107163A3 (es) 2022-03-15
KR20200046061A (ko) 2020-05-06
JP7257387B2 (ja) 2023-04-13

Similar Documents

Publication Publication Date Title
PH12020500371A1 (en) Spirocycle compounds and methods of making and using same
MX2020012797A (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso.
PH12020500372A1 (en) Spirocycle compounds and methods of making and using same
ZA201906111B (en) Cyclic di-nucleotides compounds for the treatment of cancer
MX2017011997A (es) Carbamatos de piperacina y metodos de preparacion y uso.
PH12019502646A1 (en) Pyrazole magl inhibitors
WO2018112365A3 (en) Methods of treating colorectal cancer and melanoma using parabacteroides goldsteinii
MX2017013562A (es) Reguladores de microbioma y usos relacionados de los mismos.
EA201891200A1 (ru) Композиции, содержащие бактериальные штаммы
PH12019501079A1 (en) Magl inhibitors
PH12019501097A1 (en) Magl inhibitors
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
GB2541571A (en) Pharmaceutical compositions
WO2015179559A3 (en) Pyrazole compounds and methods of making and using same
PH12019501102A1 (en) Magl inhibitors
MX2018004674A (es) Moduladores de interacción de sestrina-gator2 y sus usos.
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
MX2020008195A (es) Compuestos para el tratamiento del dolor.
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
MX2020012990A (es) Formulaciones de tegavivint y compuestos relacionados.
MX2017017119A (es) Formulacion de alta concentracion.
MX2017012342A (es) Compuestos biciclicos fusionados para el tratamiento de enfermedades,.
MY178960A (en) Hiv treatment formulation of atazanavir and cobicistat
WO2018211324A8 (en) Prodrugs for the treatment of disease
MX2018014034A (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades.